The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Alfred Olivares, global managing partner, healthcare & ...

The reversible BTK inhibitor was at least as effective as AbbVie/Johnson & Johnson's older, non-reversible drug Imbruvica ...

The first cell therapy for severe aplastic anaemia – Gamida Cell's Omisirge – has been approved by the FDA, as positive ...

Globalisation and the growth of emerging markets has created new opportunities to expand the reach for the mature portfolio.

This approach offers an enhanced therapeutic effect with minimal systemic toxicity, addressing one of oncology’s ...

Gilead Sciences' Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate ...

The company's BCMAxCD3 bispecific antibody Lynozyfic (linvoseltamab) got its first FDA approval as a fifth-line or later ...

Social determinants of health (SDOH) encompass a wide range of non-medical factors that influence health and well-being.

In line with its deregulatory stance under new Commissioner Marty Makary, the US regulator has launched TEMPO – ...

And Simon Kohl, founder and CEO of Latent Labs, knows this intimately. In a new episode of the pharmaphorum podcast, Kohl ...

At this year's ASH congress, the results of the phase 1b/2 DURGA-1 of AZD0120 – a dual BCMA and CD19-directed CAR-T therapy – ...